Curis reaffirmed a Buy at Roth

"We believe market growth (for Erivedge) will continue in 2014, providing a revenue stream and increasing visibility for Curis (CRIS -4.2%)," says analyst Joe Pantginis. He notes Erivedge revenue has grown continuously since its 2012 launch, with Roche reporting $28M in Q4 sales. Curis, of course, receives royalty payments on those sales.

Adding to that, says Pantginis, is increased clarity on Curis' internal pipeline.

Earnings coverage last Thursday

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs